HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: Romidepsin achieved accelerated approval as a class I HDAC inhibitor for peripheral T-cell lymphoma (PTCL) initially in 2011; however, its PTCL approval was withdrawn in 2021 due to its failure to reach the endpoint of PFS in combination with the chemotherapy CHOP [138].